Close menu




May 19th, 2022 | 11:14 CEST

Amazon, Edgemont Gold, Valneva - The real gold wins

  • Gold
  • Inflation
  • Biotech
Photo credits: pixabay.com

Only 'cash is king' seems to be the motto of this stock market week. High inflation is bringing tech stocks to their knees, and heavy artillery is also being brought to bear on Valneva's dead vaccine development front. The EU Commission wants to cancel the preliminary contract if the vaccine is not finally delivered within a month. Depth is also to be expected at Edgemont Gold, only this time, good things are hidden there. The gold exploration company is getting promising results from its third drill hole.

time to read: 4 minutes | Author: Juliane Zielonka
ISIN: AMAZON.COM INC. DL-_01 | US0231351067 , EDGEMONT GOLD CORP. O.N. | CA28008L1067 , VALNEVA SE EO -_15 | FR0004056851

Table of contents:


    Dennis Karp, Executive Chairman, Manuka Resources Limited
    "[...] We will trigger indirect creation of 1,665 new jobs nationwide, while directly employing 300 staff - 270 operational and 30 administrative. [...]" Dennis Karp, Executive Chairman, Manuka Resources Limited

    Full interview

     

    Amazon - Inflation influences share price

    Tech stocks like Amazon (WKN: 906866) have been in a slump for some time. One reason for this is the current inflation rate. Experts estimate it at around 7% in the USA. While the price-earnings ratio (P/E ratio) is often used to evaluate value stocks, analysts look at the value of future cash flows for tech stocks. These values are dependent on interest rates. In order to counter inflation, the US Federal Reserve (Fed) may raise interest rates. Thus, the present value of a future cash flow can change with small increases in the interest rate. Following this logic, future cash flows of tech companies such as Amazon are therefore worth less when interest rates rise, and the value of the stock falls.

    Ex-Amazon chief executive and billionaire Jeff Bezos publicly took issue with US President Joe Biden on Twitter over inflation levels. The spat began last Friday when Biden's account tweeted, "You want to lower inflation? Let's make sure the richest corporations pay their fair share." The White House was referring to an increase in the corporate tax rate for businesses. Bezos called this tweet "disinformation" and "misdirection" and further tweeted, "They failed, but if they had succeeded, inflation would be even higher than it is today, and inflation is at a 40-year high today."

    The Amazon founder is referring to Biden's "Build Back Better" plan. The plan includes measures totalling USD 700 billion: USD 400 billion to boost demand for domestic products through public spending and USD 300 billion for research and development. The goal is to create 3 million jobs. To fund it all, he wants to raise the corporate tax rate from 21% to 28%, but so far hasn't gotten around to it.

    A higher corporate tax would leave companies with less money to invest in additional capacity, economist Alan Auerbach said, according to the Associated Press. Over time, that financial burden would raise their production costs. Inflation is far from under control, and the Amazon share may fall even further in price.

    Edgemont Gold - New drill results inspire optimism

    As an alternative to tech companies in decline, popular commodities like gold remain asset classes that every investor should take a closer look at. Before an ounce is freshly minted and polished over the counter, geologists and researchers are needed to search areas for gold deposits. So that extraction plants can be built there, creating new jobs.

    One company that specializes in exploring for mineral resources is Edgemont Gold Corporation (WKN: A2QCES ), based in Vancouver, Canada. The Company is focused on exploring an area with the project name 'Dungate'. The Dungate copper-gold porphyry project is located 6km southeast of Houston in the Omineca Mining Division in British Columbia, Canada. The property originally consisted of two mineral claims.

    In 2018, Edgemont Gold Corporation acquired an interest in its first claims at Dungate. Today, it owns a total of five mineral properties covering 1,582.2 hectares that can be explored year-round on roads that are accessible year-round. Also, 'Dungate' is a safe, established mining district. Three drill holes have been completed to date. During the most recent drilling, the Company encountered an anomaly in the ground, the discovery of which will allow them to better determine the course of a gold vein. Further information can be found in the latest press release from the Canadians.

    Valneva - Development delay jeopardizes upfront contract

    Doing business with governments is a double-edged sword. On the one hand, government-mandated mass vaccination programs flush a steady cash flow into the coffers of the makers of Covid vaccines. On the other hand, the vaccine must be tailored to the current virus variant in order to be effective.

    Valneva (WKN: A0MVJZ ) is currently feeling the downside of government deals. The EU Commission wants to cancel the French-Austrian biotech company's upfront contracts for its inactivated vaccine. And it has every right to do so. After all, according to the agreement, the Commission has the right to do so if Valneva does not receive marketing authorization from the European Medicines Agency (EMA) by April 30. That date has already passed, and under the contract terms, the group has 30 days from May 13 to obtain marketing approval or propose measures to improve it.

    So in one month, research and development should be pushed hard to meet the contract terms. Shareholders have already punished Valneva: the value of the share fell by around 19% when it became clear that Valneva was experiencing delivery difficulties. The share price currently stands at EUR 10.08.

    "The European Commission's decision is regrettable, especially as we continue to receive messages from Europeans seeking a more traditional vaccine solution. We have started a dialogue with member states interested in our inactivated approach," CEO Thomas Lingelbach commented on the intention. The decision is not yet final. Instead, the EU Commission is putting the gun to the chest of the inactivated vaccine manufacturer with its intention to finally deliver.


    Investors need patience, especially in the biotech sector, because according to Friedrich von Bohlen, Dietmar Hopp's portfolio manager, research and development can easily take ten years. The EU Commission is losing ground because Valneva has not yet delivered its announced inactivated vaccine. Short-term investors have already withdrawn from the share. Amazon has also fallen considerably in price due to inflation and delays in the retail business. On the other hand, Edgemont Gold seems to be making progress. The third drill hole on their project, 'Dungate,' indicates anomalies, which can be used to better determine the course of gold veins there. A change in the current portfolio serves as its own hedge. At the International Investment Forum today, May 19, 2022, there will be the opportunity to meet more companies and their CEOs live via Zoom. Click here to register for free.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.


    Der Autor

    Juliane Zielonka

    Born in Bielefeld, she studied German, English and psychology. The emergence of the Internet in the early '90s led her from university to training in graphic design and marketing communications. After years of agency work in corporate branding, she switched to publishing and learned her editorial craft at Hubert Burda Media.

    About the author



    Related comments:

    Commented by André Will-Laudien on November 6th, 2024 | 08:00 CET

    US election and the biotech sector – A hot November is on the cards! BioNTech, Pfizer, Nyxoah, Bayer or Evotec?

    • Biotechnology
    • Biotech
    • Pharma

    With anticipation building for both the Q3 earnings season and the US election results, the markets are in a wait-and-see mode. Democrat frontrunner Kamala Harris is said to be committed to continuing the successful policies of her predecessor Joe Biden. Of course, science, research and climate protection are in the spotlight. Her rival, Donald Trump, is said to be more concerned with strengthening the traditional economy, where automotive engineering, the defense industry and security companies come to the fore. Additionally, markets are looking to central banks for cues, as lower interest rates would be a boon for the biotech sector. Here are some investment ideas for dynamic investors in this promising climate.

    Read

    Commented by Armin Schulz on November 6th, 2024 | 07:25 CET

    K+S, Almonty Industries, Barrick Gold – Commodities: The secret ingredient for your investment success

    • Mining
    • Tungsten
    • Gold
    • Commodities
    • fertilizer

    In times of economic uncertainty, investing in commodities is becoming increasingly attractive for investors. Not only do commodities offer protection against inflation, but they are also essential building blocks for technological innovation and industrial growth. This market offers natural diversification for any portfolio, from precious metals to energy sources and agricultural products. Historically, commodities have shown that they provide stable returns and long-term value appreciation potential, especially in times of crisis. For investors with foresight, the commodities sector could be a worthwhile addition to their investment strategies.

    Read

    Commented by André Will-Laudien on November 5th, 2024 | 07:30 CET

    The tension is rising! Quarterly figures from BioNTech and Evotec – Doubling potential for BioNxt, Grenke and SMCI

    • Biotechnology
    • Biotech
    • Technology

    The reporting season has just started, and the first profit warnings are already here. Grenke warns of increasing provisions, Super Micro Computer is keen to submit figures, but the auditor has resigned. There is good news, however, from Evotec, BioNTech, and BioNxt, with their bottoming phases seemingly behind them. In an environment of falling interest rates, biotech stocks could now appear in a new light. Currently, everyone is looking west because the world's largest economic power is electing a new president. Once the uncertainty clears, markets may continue their positive trend. We have some interesting investment ideas in store.

    Read